Although we are all more than familiar with the Covid-19 pandemic, Colorado businesses may not be aware of new employee sick leave laws, presently in effect, relating to the pandemic. Pursuant to the Healthy Families and Workplaces Act ("HFWA"), which was signed into law on July 14, 2020, … Read more about Mandatory Covid-19 Employee Sick Leave in Colorado: Is Your Business Compliant?
Oregon Takes the Lead on Drug Policy Reform
In the 2020 election, Oregon voters demonstrated an overwhelming appetite for drug policy reform. Election results show landslide victories for two groundbreaking measures – one decriminalizing all drugs, and one legalizing psilocybin-assisted clinical sessions. Both measures came to the ballot as … Read more about Oregon Takes the Lead on Drug Policy Reform
Colorado Marijuana Licensing
Among the country’s first states to enact marijuana-friendly legislation, Colorado legalized medical marijuana via the passage of Amendment 20 in 2000 and subsequently legalized recreational (retail) marijuana via the passage of Amendment 64 in 2012. Due to its robust implementation of these … Read more about Colorado Marijuana Licensing
Is the DEA Coming for the Hemp Industry After All?
On August 20, 2020, the United States Drug Enforcement Administration (“DEA”) issued an interim final rule (“IFR”) pertaining to the classifications of marijuana and hemp under the federal Controlled Substances Act (“CSA”) in light of the 2018 Agricultural Improvement Act (“AIA”). Because the DEA … Read more about Is the DEA Coming for the Hemp Industry After All?
DEA Announces Increased Access to Marijuana Research
On August 26, 2019, the United States Drug Enforcement Administration (“DEA”) issued a press release stating that DEA will be undertaking steps to increase access to DEA registrations required under federal law to cultivate and/or manufacture marijuana for research purposes. In making this … Read more about DEA Announces Increased Access to Marijuana Research
Largest U.S. CBD Company Hit with Warning Letter from FDA
On July 22, 2019, the United States Food and Drug Administration (“FDA”) sent a Warning Letter (the “Letter”) to Curaleaf, Inc. notifying the company that FDA considers several products Curaleaf sells on its website, specifically its “CBD Lotion,” “CBD Pain-Relief Patch,” five versions of its “CBD … Read more about Largest U.S. CBD Company Hit with Warning Letter from FDA